Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer.

Andersson Y, Bergkvist L, Frisell J, de Boniface J.

Breast Cancer Res Treat. 2019 Jun 24. doi: 10.1007/s10549-019-05328-3. [Epub ahead of print]

PMID:
31236811
2.

ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K.

Eur J Surg Oncol. 2019 Apr 22. pii: S0748-7983(19)30406-8. doi: 10.1016/j.ejso.2019.04.014. [Epub ahead of print] Review.

PMID:
31036394
3.

Generic substitution of drugs in hospitals

Johansen R, Andersson Y.

Tidsskr Nor Laegeforen. 2019 Jan 4;139(1). doi: 10.4045/tidsskr.17.0722. Print 2019 Jan 15. Norwegian.

4.

Breast-conserving surgery followed by whole-breast irradiation offers survival benefits over mastectomy without irradiation.

de Boniface J, Frisell J, Bergkvist L, Andersson Y.

Br J Surg. 2018 Nov;105(12):1607-1614. doi: 10.1002/bjs.10889. Epub 2018 Jun 21.

5.

Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.

Andersson Y, Bergkvist L, Frisell J, de Boniface J.

Breast Cancer Res Treat. 2018 Sep;171(2):359-369. doi: 10.1007/s10549-018-4820-0. Epub 2018 May 30.

PMID:
29846847
6.

Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma.

Zanjani LS, Madjd Z, Abolhasani M, Rasti A, Fodstad O, Andersson Y, Asgari M.

Biomark Med. 2018 Jan;12(1):45-61. doi: 10.2217/bmm-2017-0142. Epub 2017 Dec 15.

PMID:
29243496
7.

Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.

Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, Asgari M.

Exp Mol Pathol. 2017 Oct;103(2):218-228. doi: 10.1016/j.yexmp.2017.10.001. Epub 2017 Oct 16.

PMID:
29050853
8.

MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer.

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K.

Oncotarget. 2017 Jun 27;8(37):61800-61809. doi: 10.18632/oncotarget.18694. eCollection 2017 Sep 22.

9.

Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer.

Karakatsanis A, Daskalakis K, Stålberg P, Olofsson H, Andersson Y, Eriksson S, Bergkvist L, Wärnberg F.

Br J Surg. 2017 Nov;104(12):1675-1685. doi: 10.1002/bjs.10606. Epub 2017 Sep 6.

PMID:
28877348
10.

Blogs and the Art of Dying: Blogging With, and About, Severe Cancer in Late Modern Swedish Society.

Andersson Y.

Omega (Westport). 2017 Jan 1:30222817719806. doi: 10.1177/0030222817719806. [Epub ahead of print]

PMID:
28699836
11.

Postprandial metabolic response of breast-fed infants and infants fed lactose-free vs regular infant formula: A randomized controlled trial.

Slupsky CM, He X, Hernell O, Andersson Y, Rudolph C, Lönnerdal B, West CE.

Sci Rep. 2017 Jun 16;7(1):3640. doi: 10.1038/s41598-017-03975-4.

12.

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.

de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, Olofsson Bagge R, Sund M, Johansson H, Lundstedt D; SENOMAC Trialists’ Group.

BMC Cancer. 2017 May 26;17(1):379. doi: 10.1186/s12885-017-3361-y.

13.

Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE.

Pigment Cell Melanoma Res. 2017 Sep;30(5):467-476. doi: 10.1111/pcmr.12599. Epub 2017 Jul 4.

PMID:
28513992
14.

Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K.

Ann Surg Oncol. 2017 Jul;24(7):1916-1922. doi: 10.1245/s10434-017-5814-6. Epub 2017 Feb 21.

PMID:
28224367
15.

Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study.

de Boniface J, Frisell J, Bergkvist L, Andersson Y; Swedish Breast Cancer Group and the Swedish Society of Breast Surgery.

Br J Surg. 2017 Feb;104(3):238-247. doi: 10.1002/bjs.10411. Epub 2017 Jan 4.

PMID:
28052310
16.

Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor.

Gustafsson R, Jemth AS, Gustafsson NM, Färnegårdh K, Loseva O, Wiita E, Bonagas N, Dahllund L, Llona-Minguez S, Häggblad M, Henriksson M, Andersson Y, Homan E, Helleday T, Stenmark P.

Cancer Res. 2017 Feb 15;77(4):937-948. doi: 10.1158/0008-5472.CAN-16-1476. Epub 2016 Nov 29.

17.

Klotho and smoking--An interplay influencing the skeletal muscle function deficits that occur in COPD.

Patel MS, Donaldson AV, Lewis A, Natanek SA, Lee JY, Andersson YM, Haji G, Jackson SG, Bolognese BJ, Foley JP, Podolin PL, Bruijnzeel PL, Hart N, Hopkinson NS, Man WD, Kemp PR, Polkey MI.

Respir Med. 2016 Apr;113:50-6. doi: 10.1016/j.rmed.2016.02.004. Epub 2016 Feb 15.

18.

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S.

Br J Cancer. 2015 Dec 1;113(11):1548-55. doi: 10.1038/bjc.2015.380. Epub 2015 Nov 10.

19.

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH.

BMC Cancer. 2015 Jul 24;15:543. doi: 10.1186/s12885-015-1557-6.

20.

The incidence of acute gastrointestinal illness in Sweden.

Hansdotter FI, Magnusson M, Kühlmann-Berenzon S, Hulth A, Sundström K, Hedlund KO, Andersson Y.

Scand J Public Health. 2015 Jul;43(5):540-7. doi: 10.1177/1403494815576787. Epub 2015 May 12.

21.

Increased risk of renal biopsy complications in patients with IgA-nephritis.

Peters B, Stegmayr B, Andersson Y, Hadimeri H, Mölne J.

Clin Exp Nephrol. 2015 Dec;19(6):1135-41. doi: 10.1007/s10157-015-1121-3. Epub 2015 May 8.

PMID:
25951807
22.

Impact of probiotics during weaning on the metabolic and inflammatory profile: follow-up at school age.

Karlsson Videhult F, Andersson Y, Öhlund I, Stenlund H, Hernell O, West CE.

Int J Food Sci Nutr. 2015;66(6):686-91. doi: 10.3109/09637486.2015.1025717. Epub 2015 Apr 1.

PMID:
25830947
23.

European monitoring systems and data for assessing environmental and climate impacts on human infectious diseases.

Nichols GL, Andersson Y, Lindgren E, Devaux I, Semenza JC.

Int J Environ Res Public Health. 2014 Apr 9;11(4):3894-936. doi: 10.3390/ijerph110403894.

24.

The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.

Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y.

J Ovarian Res. 2014 Feb 15;7:23. doi: 10.1186/1757-2215-7-23.

25.

Phenotypic characteristics associated with reduced short physical performance battery score in COPD.

Patel MS, Mohan D, Andersson YM, Baz M, Samantha Kon SC, Canavan JL, Jackson SG, Clark AL, Hopkinson NS, Natanek SA, Kemp PR, Bruijnzeel PLB, Man WD, Polkey MI.

Chest. 2014 May;145(5):1016-1024. doi: 10.1378/chest.13-1398.

PMID:
24337162
26.

A study of clinical complications and risk factors in 1,001 native and transplant kidney biopsies in Sweden.

Peters B, Andersson Y, Stegmayr B, Mölne J, Jensen G, Dahlberg P, Holm-Gunnarsson I, Ekberg J, Bjurström K, Haux SB, Hadimeri H.

Acta Radiol. 2014 Sep;55(7):890-6. doi: 10.1177/0284185113506190. Epub 2013 Sep 25.

PMID:
24068748
27.

Authors' reply: causes of false-negative sentinel node biopsy in patients with breast cancer (Br J Surg 2013; 100: 775-783).

de Boniface J, Andersson Y.

Br J Surg. 2013 Sep;100(10):1399. doi: 10.1002/bjs.9251. No abstract available.

PMID:
23939860
28.

Epidemiology and estimated costs of a large waterborne outbreak of norovirus infection in Sweden.

Larsson C, Andersson Y, Allestam G, Lindqvist A, Nenonen N, Bergstedt O.

Epidemiol Infect. 2014 Mar;142(3):592-600. doi: 10.1017/S0950268813001209. Epub 2013 May 29.

PMID:
23714107
29.

Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y.

Int J Cancer. 2013 Sep 15;133(6):1497-506. doi: 10.1002/ijc.28158. Epub 2013 Apr 17.

30.

Causes of false-negative sentinel node biopsy in patients with breast cancer.

Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L.

Br J Surg. 2013 May;100(6):775-83. doi: 10.1002/bjs.9085. Epub 2013 Feb 22.

PMID:
23436699
31.

Public health. Monitoring EU emerging infectious disease risk due to climate change.

Lindgren E, Andersson Y, Suk JE, Sudre B, Semenza JC.

Science. 2012 Apr 27;336(6080):418-9. doi: 10.1126/science.1215735. No abstract available.

PMID:
22539705
32.

Probiotic effects on T-cell maturation in infants during weaning.

West CE, Hernell O, Andersson Y, Sjöstedt M, Hammarström ML.

Clin Exp Allergy. 2012 Apr;42(4):540-9. doi: 10.1111/j.1365-2222.2011.03941.x.

PMID:
22417212
33.

Prediction of non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastases: evaluation of the tenon score.

Andersson Y, Frisell J, de Boniface J, Bergkvist L.

Breast Cancer (Auckl). 2012;6:31-8. doi: 10.4137/BCBCR.S8642. Epub 2012 Jan 30.

34.

Public health burden due to infections by verocytotoxin-producing Escherichia coli (VTEC) and Campylobacter spp. as estimated by cost of illness and different approaches to model disability-adjusted life years.

Toljander J, Dovärn A, Andersson Y, Ivarsson S, Lindqvist R.

Scand J Public Health. 2012 May;40(3):294-302. doi: 10.1177/1403494811435495. Epub 2012 Feb 6.

PMID:
22312030
35.

Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer.

Andersson Y, de Boniface J, Jönsson PE, Ingvar C, Liljegren G, Bergkvist L, Frisell J; Swedish Breast Cancer Group; Swedish Society of Breast Surgeons.

Br J Surg. 2012 Feb;99(2):226-31. doi: 10.1002/bjs.7820. Epub 2011 Dec 19.

PMID:
22180063
36.

Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.

Risberg K, Fodstad Ø, Andersson Y.

PLoS One. 2011;6(9):e24012. doi: 10.1371/journal.pone.0024012. Epub 2011 Sep 7.

37.

Immunotoxins: a promising treatment modality for metastatic melanoma?

Risberg K, Fodstad O, Andersson Y.

Ochsner J. 2010 Fall;10(3):193-9.

38.

Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins.

Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y.

J Immunother. 2011 Jun;34(5):438-47. doi: 10.1097/CJI.0b013e31821e00ae.

PMID:
21577141
39.

Source attribution of human Salmonella cases in Sweden.

Wahlström H, Andersson Y, Plym-Forshell L, Pires SM.

Epidemiol Infect. 2011 Aug;139(8):1246-53. doi: 10.1017/S0950268810002293. Epub 2010 Oct 14.

PMID:
20943003
40.

Eye-opening approach to norovirus surveillance.

Hulth A, Andersson Y, Hedlund KO, Andersson M.

Emerg Infect Dis. 2010 Aug;16(8):1319-21. doi: 10.3201/eid1608.100093. No abstract available.

41.

A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y.

Cancer Immunol Immunother. 2010 Nov;59(11):1665-74. doi: 10.1007/s00262-010-0892-3. Epub 2010 Jul 16.

42.

Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.

Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L.

J Clin Oncol. 2010 Jun 10;28(17):2868-73. doi: 10.1200/JCO.2009.24.5001. Epub 2010 May 10.

PMID:
20458033
43.

Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.

Risberg K, Fodstad O, Andersson Y.

J Immunother. 2010 Apr;33(3):272-8. doi: 10.1097/CJI.0b013e3181c54991.

PMID:
20445347
44.

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.

Andersson Y, Engebraaten O, Fodstad Ø.

Br J Cancer. 2009 Oct 20;101(8):1307-15. doi: 10.1038/sj.bjc.6605312. Epub 2009 Sep 22.

45.

A foodborne norovirus outbreak at a manufacturing company.

Zomer TP, De Jong B, Kühlmann-Berenzon S, Nyrén O, Svenungsson B, Hedlund KO, Ancker C, Wahl T, Andersson Y.

Epidemiol Infect. 2010 Apr;138(4):501-6. doi: 10.1017/S0950268809990756. Epub 2009 Sep 21.

PMID:
19765351
46.

Formula feeding skews immune cell composition toward adaptive immunity compared to breastfeeding.

Andersson Y, Hammarström ML, Lönnerdal B, Graverholt G, Fält H, Hernell O.

J Immunol. 2009 Oct 1;183(7):4322-8. doi: 10.4049/jimmunol.0900829. Epub 2009 Sep 4.

47.

Hepatitis A risk in travelers.

Askling HH, Rombo L, Andersson Y, Martin S, Ekdahl K.

J Travel Med. 2009 Jul-Aug;16(4):233-8. doi: 10.1111/j.1708-8305.2009.00307.x. Erratum in: J Travel Med. 2009 Nov-Dec;16(6):412.

48.

Genetic diversity among food-borne and waterborne norovirus strains causing outbreaks in Sweden.

Lysén M, Thorhagen M, Brytting M, Hjertqvist M, Andersson Y, Hedlund KO.

J Clin Microbiol. 2009 Aug;47(8):2411-8. doi: 10.1128/JCM.02168-08. Epub 2009 Jun 3.

49.

The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro.

Risberg K, Fodstad Ø, Andersson Y.

Int J Cancer. 2009 Jul 1;125(1):23-33. doi: 10.1002/ijc.24317.

50.

Sc(2)MgGa(2) and Y(2)MgGa(2).

Sahlberg M, Andersson Y.

Acta Crystallogr C. 2009 Mar;65(Pt 3):i7-8. doi: 10.1107/S0108270109000766. Epub 2009 Feb 7.

PMID:
19265212

Supplemental Content

Loading ...
Support Center